Basilea Pharmaceuticals is a leader in targeted oncology small-molecules, novel antibiotics and antifungals. Since its listing in 2004 (SIX: BSLN), Basilea has led with two anti-infectives treatments: Zevtera, an antibiotic for severe hospital bacterial infections and Cresemba (isavuconazole) for invasive fungal infections.

Award
  • Nominated in 2020

  • Winner in 2021